20 July 2017 EMA/CAT/462094/2017 Inspections, Human Medicines Pharmacovigilance and Committees Division

CAT monthly report of application procedures, guidelines and related documents on advanced therapies July 2017 meeting

The Committee for Advanced Therapies (CAT) held its 95th CAT meeting on 12 – 14 July 2017. The CAT Monthly Report includes statistical data on CAT scientific recommendations on Advanced Therapy Medicinal Product (ATMP) classification, certifications, initial evaluations, CAT contributions to Scientific Advice and Paediatric Investigation Plans, as well as variations, line extensions, renewals.

Scientific recommendation on advanced therapy product classification Further to consultation with the European Commission, the CAT finalised 4 scientific recommendations on the classification of advanced therapy medicinal products. The following products were classified as somatic cell therapy medicinal products: •

Autologous uncultured cells of stromal vascular fraction intended for the relief of symptoms of osteoarthritis.



Human umbilical cord blood-derived mesenchymal stem cells intended for the treatment of atopic dermatitis.

The following products were classified as tissue engineered products: •

Autologous keratinocytes intended for the treatment of burns and chronic, severe wounds.



Autologous chondrocytes intended for the repair of single symptomatic cartilage defects of the knee.

Organisational matters •

CAT adopted the concept paper on the revision of the guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. The document will be published shortly.



CAT finalised the programme of the Expert Meeting on adeno-associated viral (AAV) vectors that will take place on 6 September 2017. This meeting is not open to the public.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.



CAT discussed the preparation of the Expert meeting on genome editing that will take place on 18 October 2017. This meeting is organised jointly by CAT and the CHMP Pharmacogenomics Working Party (PGWP). CAT and PGWP members will discuss with experts from academia and industry the state of art in genome editing technologies, the current product developments and the potential consequences on existing EMA guidance. This meeting is not open to the public.

New ATMP related documents published on the EMA Website •

Development of non-substantially manipulated cell-based ATMPs: flexibility introduced via the application of the risk-based approach



GLP requirement for ATMPs

Overview of product-related activities The Committee discussed ongoing evaluation procedures for ATMPs and other related procedures as summarised in the following tables: Initial Evaluation of Marketing Authorisation Applications (MAA) for ATMP 2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

3

1

2

3

2

2

1

1

1

16

1

0

1ii

1ii

2

1

1

2

1

10*

1i

0

1ii

0

0

0

2iii

0

0

4

1

1i

0

0

2

0

0

0

0

4

Submitted MAAs Positive draft Opinion Negative draft opinions Withdrawals

2

Ongoing MAAs * Corresponding to 9 ATMPs I Same product (Cerepro) ii Same product (Glybera) iii CAT adopted two negative draft opinions for the same product (Heparesc)

Variations (Type II) for authorised ATMP

Positive

2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

0

0

1

1

9

4

3

6

3

27

Opinion

Scientific recommendation on advanced therapy classification 2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

Submitted

22

19

12

22

20

28

61

60

28

272

Adopted

12

27

12

16

23

29

31

87

34

271

CAT monthly report of application procedures, guidelines and related documents on advanced therapies EMA/462094/2017

Page 2/3

Certification of quality and non-clinical data for small and medium-sized enterprises developing ATMPs 2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

Submitted

1

0

0

1

3

1

1

2

1

10

Adopted

0

1

0

1

1

2

1

1

3

10

Scientific advice procedure for ATMPs

Number of

2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

17

19

21

19

23

33

39

46

27

244

procedures

Paediatric Investigation Plans (PIP) for ATMPs

Number of

2009

2010

2011

2012

2013

2014

2015

2016

2017

Total

3

4

4

8

5

4

3

5

1

37

procedures

Prime Eligibility for ATMPs

Discussed Granted

2016

2017

Total

22

13

35

8

4

12

Upcoming meetings following the July 2017 CAT meeting The 96th meeting of the CAT will be held on 6 – 8 September 2017. NOTE: 1. This Monthly Report, the Agenda of this meeting, the Minutes of the previous CAT meeting and other documents can be found on the internet at the following location: European Medicines Agency - Committee meeting reports - CAT: Committee meeting reports 2. Specific information related to ATMPs and the activities of the CAT (role, responsibilities and composition) can be found at: European Medicines Agency - CAT - Committee for Advanced Therapies (CAT)

Thorsten Olski Head of Scientific Committees Secretariat Tel.: (+44-20) 3660 7684 [email protected]

CAT monthly report of application procedures, guidelines and related documents on advanced therapies EMA/462094/2017

Page 3/3

Committee for Advanced Therapies (CAT) - European Medicines Agency

Jul 20, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone +44 (0)20 3660 6000 ... industry the state of art in genome editing technologies, the current product developments and the potential consequences on existing EMA guidance.

107KB Sizes 0 Downloads 145 Views

Recommend Documents

Committee for Advanced Therapies (CAT) - Minutes of the meeting on ...
6 October 2017. EMA/CAT/602703/2017. Inspections, Human Medicines Pharmacovigilance and Committees Division. Committee for Advanced Therapies (CAT). Minutes of the meeting on 06-08 September 2017. Chair: Martina Schüßler-Lenz; Vice-Chair: Ilona Rei

Organising committee - European Medicines Agency - Europa EU
Jul 31, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ... Human Medicines Research and Development Support Division.

CAT agenda for the written procedure - European Medicines Agency
Aug 7, 2017 - adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

CAT agenda for the written procedure - European Medicines Agency
Aug 7, 2017 - Re-examination of initial application procedures under Article 9(2) of ..... the CAT would like to discuss with company representatives in person.

CAT meetings 2016, 2017, 2018 - European Medicines Agency
May 3, 2016 - Send a question via our website www.ema.europa.eu/contact. © European Medicines Agency, 2016. Reproduction is authorised provided the ...

Notice - European Medicines Agency
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti

Report - European Medicines Agency
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.

CAT work plan 2017 - European Medicines Agency - Europa EU
Apr 12, 2017 - Member. Marc Turner. Scottish National Blood Transfusion. Service .... CAT will collaborate with the BWP and the HMA innovation network on this ... 1.3.3. Addressing the Environmental Risk assessment of ATMPs containing.

Monthly report CAT May 2016 - European Medicines Agency - Europa ...
May 26, 2016 - Send a question via our website www.ema.europa.eu/contact ... treatment of acute graft-versus-host disease grades III and IV resistant to first ...

CAT meetings in 2019, 2020 and 2021 - European Medicines Agency
15, 16, 17. 22, 23, 24. 14, 15, 16. May. 22, 23, 24. 18, 19, 20. 10, 11, 12. June. 19, 20, 21. 17, 18, 19. 16, 17, 18. July. 17, 18, 19. 15, 16, 17. 14, 15, 16. August.

Monthly report CAT July 2017 - European Medicines Agency - Europa ...
Jul 20, 2017 - CAT monthly report of application procedures, guidelines ... industry the state of art in genome editing technologies, the current product developments and ... Development of non-substantially manipulated cell-based ATMPs: ...

Monthly report CAT May 2016 - European Medicines Agency - Europa ...
May 26, 2016 - Send a question via our website www.ema.europa.eu/contact ... treatment of acute graft-versus-host disease grades III and IV resistant to first ...

Human Medicines Highlights Newsletter - European Medicines Agency
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. • Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. • Feraccru (ferr

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...

EMA leaflet for patients - European Medicines Agency
authorisation application to EMA. Each new medicine is ... EMA encourages research and development of new ... in the EU, we have access to the best scientific.

Human Medicines Highlights Newsletter - European Medicines Agency
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...

Agenda - European Medicines Agency - europa.eu
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...

Finasteride - European Medicines Agency - europa.eu
Apr 25, 2018 - Page 2/8. Product Name (in authorisation country). MRP/DCP. Authorisation number. National Authorisation Number. MAH of product in the.

Agenda - European Medicines Agency - europa.eu
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. •. Scanning the horizon for 2016 – 2018. Peter Arlett, EMA.

Human medicines highlights newsletter - European Medicines Agency
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. • Workshop on identifying opportunities for 'big data' in medicines development and ...

Human Medicines Highlights Newsletter - European Medicines Agency
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.

Agenda - European Medicines Agency veterinary medicines ...
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung

Human Medicines Highlights Newsletter - European Medicines Agency
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.